anticorps cb984, anticorps ptprm, anticorps zgc:110218, anticorps PTPRM, anticorps p-ptp-mu, anticorps ptprl1, anticorps r-ptpu, anticorps rptpm, anticorps rptpu, anticorps PTPRL1, anticorps R-PTP-MU, anticorps RPTPM, anticorps RPTPU, anticorps hR-PTPu, anticorps RPTPmu, anticorps mKIAA4044, anticorps protein tyrosine phosphatase, receptor type, M, a, anticorps protein tyrosine phosphatase, receptor type M, anticorps protein tyrosine phosphatase, receptor type, M, b, anticorps receptor-type tyrosine-protein phosphatase mu, anticorps protein tyrosine phosphatase, receptor type, M, anticorps ptprma, anticorps PTPRM, anticorps ptprmb, anticorps ptprm, anticorps LOC100550127, anticorps LOC100564083, anticorps Ptprm
Sujet
PTP mu, a R2A receptor protein tyrosine phosphatase, is composed of an extracellular segment containing a MAM domain, an immunoglobulin domain and four fibronectin type III repeats, a transmembrane segment, and two intracellular protein phosphatase domains. PTP mu has been shown to affect cell-cell aggregation, regulate cardiac myocyte Kv1.5 channel expression, and promote neurite outgrowth of retinal ganglion cells. The human PTP mu gene is localized on chromosome 18pter-q11, a region with frequent abnormalities implicated in human cancer. PTP mu may be important in responses to pathological conditions associated with the loss of cell-cell interactions in the heart.